Brief by Shorts91 Newsdesk / 09:28am on 23 Oct 2024,Wednesday International
The NHS in England has rejected the use of donanemab, a new Alzheimer's drug, despite the UK’s medicines regulator indicating it could be licensed. The National Institute of Health and Care Excellence (NICE) determined that donanemab "does not currently demonstrate value for the NHS." This rejection is notable as it is the second time in a few months that NICE has turned down a new treatment for Alzheimer's. Donanemab, produced by pharmaceutical company Eli Lilly, is designed as a targeted antibody drug aimed at slowing the early stages of Alzheimer's disease, highlighting ongoing challenges in accessing effective treatments.
